Efalizumab
- Generic Name
- Efalizumab
- Drug Type
- Biotech
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
- Conditions
- Kidney TransplantationChronic Kidney Failure
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00472082
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT00442650
- Locations
- π¨π
Merck Serono Medical Information Office, Geneva, Switzerland
Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 12
- Registration Number
- NCT00368654
- Locations
- πΊπΈ
University of California, Davis Medical Center Department of Dermatology, Sacramento, California, United States
Pilot Study of Raptiva to Treat Sjogren's Syndrome
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 10
- Registration Number
- NCT00344448
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
- Conditions
- Psoriasis
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT00338143
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00336973
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
- Conditions
- Psoriasis
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00312026
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- The Cleveland Clinic
- Registration Number
- NCT00308204
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2007-07-13
- Lead Sponsor
- Derm Research, PLLC
- Target Recruit Count
- 20
- Registration Number
- NCT00302445
- Locations
- πΊπΈ
Dermatology Associates, PLLC, Seattle, Washington, United States
πΊπΈDerm Research, PLLC, Louisville, Kentucky, United States
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Candidates for Systemic Therapy for PsoriasisPsoriasis
- Interventions
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 189
- Registration Number
- NCT00287118
- Locations
- π¨π
Medical Information Switzerland, Geneva, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.